Beyond weight loss, early exploratory data suggest potential benefits including: Reductions in HbA1c (a marker of blood sugar control) in people with type 2 diabetes Improvements in lipid profiles (cholesterol and triglycerides) Reductions in liver fat, which may be relevant for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), though these findings are preliminary Possible cardiovascular benefits
Put the practical answer near the top before the commercial call to action
Prog Cardiovasc Dis, 40(3), 265-86
[12] Other subtypes include malignant melanoma NOS (Not Otherwise Specified), balloon cell melanoma, malignant melanoma regressing, amelanotic melanoma and malignant melanoma in junctional naevus, among others
This segment of patients may prioritize convenience and tolerability, and/or have more modest weight loss goals
In comparison to other hypoglycemic drugs, it was found that SGLT2 inhibitors showed a greater efficacy than DPP4 inhibitors and similar or slightly less efficacy compared to metformin and TZDs (15,141)
.jpg)
